Medical Radiology and Radiation Safety. 2022. Vol. 67. № 1

Investigation of the Microelement Content of Intervertebral Disc
in Osteochondrosis of the Lumbar Spine

S.S. Kochkartaev¹, E.A. Danilova², Sh.Sh. Shatursunov¹,
N.S. Osinskaya²

¹Republican Scientific and Practical Medical Center of Traumatology and Orthopedics, Tashkent, Uzbekistan

²Institute of Nuclear Physics, Tashkent, Uzbekistan

Contact person: Danilova Elena Artovazdovna: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

The progressive prevalence, significant economic losses, the cost of compulsory health insurance and high-tech medical care have turned the problem of lumbar osteochondrosis into a socially significant issue. The relevance of this problem is dictated by the need to study the etiopathogenesis of the course of degenerative changes for an integrated approach when choosing an adequate treatment.

The progression of the pathological process in the spine significantly contributes to changes in the metabolism of connective tissue, which is closely associated with the violation of microelements.

Purpose: Evaluation of changes in the homeostasis of the intervertebral disc, in particular the study of the microelement composition of the intervertebral disc at various stages of development of hernias of the lumbar spine using instrumental neutron activation analysis.

Material and methods: The studied biomaterial was obtained intraoperatively, with traditional microdiscectomy in herniations of the spine at the level of VL3-4, VL4-5, VL5-S1. By the method of instrumental neutron activation analysis, a study of biomaterials, represented by tissue fragments of the remote part of the hernia of the intervertebral disc, located at different stages of the degenerative process, was carried out.

Results: The quantitative content of 22 macro- and microelements in the removed fragments was determined. As a result of the data obtained, it was found that in the tissues of the intervertebral discs, a gradual change in the content of a number of essential elements occurs, depending on the stage of development of the degeneration process.

Conclusion: Changes in the microelement composition indicate metabolic processes occurring in the intervertebral discs, and the relationship of the microelement composition of the disc tissue and the course of the degenerative process can be used to predict the condition of the patient and choose an adequate treatment.

Keywords: osteochondrosis, disc herniation, intervertebral discs, neutron activation analysis, microelements

For citation: Kochkartaev SS, Danilova EA, Shatursunov ShSh, Osinskaya NS. Investigation of the Microelement Content of Intervertebral Disc in Osteochondrosis of the Lumbar Spine. Medical Radiology and Radiation Safety. 2022;67(1):83-86.

DOI: 10.12737/1024-6177-2022-67-1-83-86

References

1. Drivotinov B.V., Ban D.S. The Role of the Reactive-Inflammatory and Scar-Adhesive Process in the Pathogenesis, Clinic and Treatment of Neurological Manifestations of lumbar osteochondrosis. Meditsinskiy zhurnal. Minsk. 2006;2:21˗23 (In Russ.).

2. Zhuravlev Yu.I., Nazarenko G.I., Cherkashov A.M., et all. Prediction of the Outcome of Surgical Treatment of Degenerative Disease of the Intervertebral Discs of the Lumbosacral Spine. Voprosy neyrokhirurgii im. N.N. Burdenko. 2009;1:42˗47 (In Russ.).

3. Korzh N.A., Prodan A.I., Barysh A.E. Degenerative Diseases of the Spine and Their Structural and Functional Classification. Ukrainian Neurosurgical Journal. 2004;3:27-30 (In Ukr.).

4. Jiil P.G., Urban and Sally Roberts. Degeneration of the Intervertebral Disc. Arthritis Research Therapy. 2003;5;3:120-130.

5. Vasilyeva I.G., KHizhnyak M.V., et al. Degeneration of Intervertebral Discs and Methods for its Biological Correction. Ukrainian Neurosurgical Journal. 2010;1:16˗23 (In Ukr.).

6. Zaydman A.M., Filippova G.N. Strukturno-Metabolicheskiye Osobennosti Mezhpozvonkovogo Diska pri Osteokhondroze i Vozmozhnosti Yego Korrektsii = Structural and Metabolic Features of the Intervertebral Disc in Osteochondrosis and the Possibility of its Correction. Patologiya Pozvonochnika. Leningrad Publ., 1980. P. 88-94 (In Russ.).

7. Tsivyan YA.L., Raykhinshteyn V.YE. Mezhpozvonkovyye Diski: Nekotoryye Aspekty Fiziologii i Biomekhaniki = Intervertebral Discs: Some Aspects of Physiology and Biomechanics. Novosibirsk, Nauka. Sib. Otdeleniye Publ., 1977. 165 p. (In Russ.).

8. Avtsyn A.P., ZHavoronkov A.A. Mikroelementozy Cheloveka = Microelements of a Person. Moscow, Meditsina Publ., 1991. 496 p. (In Russ.).

9. Vernadskiy V.I. Khimicheskiy Sostav Zhivogo Veshchestva = The Chemical Composition of Living Matter. Moscow Publ., 1922. (In Russ.).

10. Byvaltsev V., Belykh E., Panasenkov S., et al. Nanostructural Changes of Intervertebral Disc after Diode Laser Ablation. World Neurosurgery. 2012;77;1:6–7.

11. Skalnyy A.V., Rudakov I.A. Bioelementy v Meditsine = Bioelements in Medicine. Moscow, Oniks 21 vek, Mir Publ., 2004. 272 p. (In Russ.).

12. Babenko G.A., Reshetkina A.P. Primeneniye Mikroelementov v Meditsine = The Use of Trace Elements in Medicine. Kiev Publ., 1971. 311 р. (In Russ.).

13. Mednis I.V. Gamma-Izlucheniye Radionuklidov, Primenyayemykh v Neytronno-Aktivatsionnom Analize = Gamma Radiation of Radionuclides Used in Neutron Activation Analysis. Directory. Riga, Zinatne Publ., 1987. 212 р. (In Russ.).

14. Podkolzin A.A., Dontsov V.I. Immunitet i Mikroelementy = Immunity and Microelements. Moscow Publ., 1994. 144 р. (In Russ.). 

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 17.07.2021. 

Accepted for publication: 05.09.2021

 

 

Medical Radiology and Radiation Safety. 2022. Vol. 67. № 1

Case of a Patient with Cervical Cancer after Wertheim Surgery
who Underwent Minimally Invasive Treatment of Giant Lymphocele
and Related Secondary Complications

N.S. Skreptsova, S.O. Stepanov, A.D. Kaprin, A. A. Kostin,
A.V. Boyko, L.V. Demidova, E.G. Novikova, L.A. Mitina,
D.V. Dolgacheva, N.V. Zelich, L.G. Serova 

National Medical Research Radiological Center, Moscow, Russia

Contact person: Skreptsova Natalia Sergeevna: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABCTRACT

An experience of successful treatment of giant lymphocele and related secondary complications, such as signs of hydronephrosis of both kidneys of a patient after Wertheim surgery in case of cervical disease before radiotherapy is described. A complex of ultrasound studies using 3 types of echographic picture of the lymphocele was applied, which made it possible to determine the rational management of the patient using the technique of invasive sonography. Ultrasound examination, on the 17th day after the operation, revealed lymphocele in the iliac regions (1450 ml on the right, 1290 ml on the left) and signs of hydronephrosis of both kidneys. Drains under the control of sonography in both the lymphatic cavity were set up. Signs of hydronephrosis of both kidneys ceased to be located on the 2nd day after the installation of drains. Drains were removed after 13 days. During further ultrasound examinations of the patient, the lymphocele and signs of hydronephrosis were not rendered. Ultrasound examinations were performed on the 3rd, 7th, 12th, 21st, 35th, 62nd, 145th day after drains were removed.

Keywords: cervical cancer, pelvic lymphadenectomy, radiation therapy, ultrasound, invasive sonography, lymphocele, lymphatic cyst

For citation: Skreptsova NS, Stepanov SO, Kaprin AD, Kostin AA, Boyko AV, Demidova LV, Novikova EG, Mitina LA, Dolgacheva DV, Zelich NV, Serova LG. Case of a Patient with Cervical Cancer after Wertheim Surgery who Underwent Minimally Invasive Treatment of Giant Lymphocele and Related Secondary Complications. Medical Radiology and Radiation Safety. 2022;67(1):99-102.

DOI: 10.12737/1024-6177-2022-67-1-99-102

References

1. Ed. Kaprin A.D., Starinskiy V.V., Petrova G.V. The State of Cancer Care in the Population of Russia in 2018. Moscow, MNIOI im. P.A. Gertsena Publ., 2019. P. 5 (In Russ.).

2. Ed. Chissov V.I, Davydov M.I., Aleksandrova L.M. Oncology. National Guidelines. Short Version. Мoscow, GEOTAR-Media Publ., 2017. P. 113-117 (In Russ.).

3. Boyko A.V., Dunayeva E.A., Demidova L.V., Dubovetskaya O.B., Serova L.G., Alekseyev B.Ya. Implemenation of Radiation Therapy for Locally Advanced and Recurrent Cervical Cancer Complicated by Ureterohydronephrosis. Meditsinskaya radiologiya i radiatsionnaya bezopasnost = Medical Radiology and Radiation Safety. 2019;64;4:41–47. DOI: 10.12737/article_5d1108af5d48d3.68800561. (In Russ.).

4. Makatsariya N.A. Ernst Wertheim. Akusherstvo, Ginekologiya i Reproduktsiya = Obstetrics, Gynecology and Reproduction. 2014;8;2:149-150 (In Russ.).

5. Ballester M., Bendifallah S., Daraï E. European guidelines (ESMO-ESGO- ESTRO consensus conference) for the Management of Endometrial Cancer. Bull. Cancer 2017;104;12:1032–1038. PMID: 29173977. DOI: 10.1016/j.bulcan.2017.10.006.

6. Cibula D., Pötter R., Planchamp F., et al. The European Society of Gynaecological Oncology. European Society for Radiotherapy and Oncology. European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Radiother. Oncol. 2018;127;3:404–416. PMID: 29728273. DOI: 10.1016/j.radonc.2018.03.003.

7. Skreptsova N.S., Stepanov S.O., Guts O.V., Prozorova E.V. Invasive Sonography in Diagnostics and Treatment of Lymphocele of Patients after Pelvic Lymphadenectomy. Luchevaya Diagnostika i Terapiya = Diagnostic Radiology and Radiotherapy. 2013;3;4:83-88 (In Russ.).

8. Akhmetzyanov F.SH., Mardanova S.M. Ultrasound in Early Postoperative Period in Patients after Cancer Surgery on the Pelvic Organs. Sovremennaya Meditsina: Aktualnyye Voprosy = Modern Medicine. Actual Issues. 2016;7;49:21-33 (In Russ.).

9. Rogovskaya T.T., Berlev I.V. Lymphatic Cysts after Gynecological Cancer Surgery: Risk Factors, Diagnosis and Treatment. Opukholi Zhenskoy Reproduktivnoy Sistemy = Tumors of Female Reproductive System. 2018;14;4:72-79. DOI: 10.17650/1994-4098-2018-14-4-72-79. (In Russ.).

10. Ghezzi F., Uccella S., Cromi A. et al. Lymphoceles, Lymphorrhea, and Lymphedema after Laparoscopic and Open Endometrial Cancer Staging. Ann. Surg. Oncol. 2012;19;1:259–267. PMID: 21695563. DOI: 10.1245/s10434-011-1854-5.

11. Kim Y.H., Shin H.J., Ju W., Kim S.C. Prevention of Lymphocele by Using Gelatinthrombin Matrix as a Tissue Sealant after Pelvic Lymphadenectomy in Patients with Gynecologic Cancers: a Prospective Randomized Controlled Study. J. Gynecol. Oncol. 2017;28;3:37. PMID: 28382800. DOI: 10.3802/jgo.2017.28.e37.

12. Kondo E., Tabata T., Shiozaki T. et al. Large or Persistent Lymphocyst Increases the Risk of Lymphedema, Lymphangitis, and Deep Vein Thrombosis after Retroperitoneal Lymphadenectomy for Gynecologic Malignancy. Arch. Gynecol. Obstet. 2013;288;3:587–593. PMID: 23455541. DOI: 10.1007/s00404-013-2769-0.

13. Tinelli A., Mynbaev O.A., Tsin D.A., et al. Lymphocele Prevention after Pelvic Laparoscopic Lymphadenectomy by a Collagen Patch Coated with Human Coagulation Factors: a Matched Case-Control Study. Int. J. Gynecol. Cancer. 2013;23;5:956–963. PMID: 23574881. DOI: 10.1097/ IGC.0b013e31828eeea4.

14. Yin H., Gui T. Comparative Analyses of Postoperative Complications and Prognosis of Different Surgical Procedures in Stage II Endometrial Carcinoma Treatment. Onco. Targets Ther. 2016;9:781–786. PMID: 26937200. DOI: 10.2147/OTT.S95806.

15. Zikan M., Daniela F., Pinkavova I., et al.  A Prospective Study Examining the Incidence of Asymptomatic and Symptomatic Lymphoceles Following Lymphadenectomy in Patients with Gynecological Cancer. Gynecol. Oncol. 2015;137;2:291–298.  PMID: 25720294. DOI: 10.1016/j.ygyno.2015.02.016.

16. Vaskovskaya O.V., Asabayeva R.I., Digay L.K., Kokoshko A.I. Complications after Gynecological Cancer Expanded Operations. Nauchnoye Obozreniye. Meditsinskiye Nauki = Science-Review. 2014;1:58-59. URL: https://science-medicine.ru/ru/article/view?id=63. (In Russ.).

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution: N.S. Skreptsova, S.O. Stepanov: obtaining data for analysis, analysis of the obtained data, writing the text of the manuscript

A.D. Kaprin, A.A. Kostin, A.V. Boyko, L.A. Mitin: development of the theoretical basis of the study

L.V. Demidova, D.V. Dolgacheva: scientific editing of the text of the manuscript

N.V. Evtyagin, L.G. Serov: review of publications on the topic of the article

The patient signed an informed consent to participate in the study.

Article received: 17.09.2021.  Accepted for publication: 05.12.2021 

Medical Radiology and Radiation Safety. 2022. Vol. 67. № 1

Hyperthermic Methods in Conservative
and Palliative Treatment of Oncological Patients.
Part 1. Loco-Regional Hyperthermia

O.K. Kurpeshev¹, J. Van Der Zee²

¹ Siberian Scientific Research Institute of Hyperthermia, Novosibirsk, Russia.

² Erasmus Medical Centre, Cancer Institute, Rotterdam, The Netherlands

Contact person: Orazakhmet Kerimbaevich Kurpeshev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

CONTENTS

The analysis of the results of conservative and palliative treatment of cancer patients with the use of loco-regional hyperthermia (LRHT) alone or in combination with various methods of anticancer therapy was carried out. The data obtained showed that LRHT significantly increases the immediate results of radiation and / or chemotherapy, has a pronounced palliative effect, and in some cases provides long-term local control. In incurable patients who have exhausted the "limit" of chemotherapy and / or radiation therapy, its use for palliative purposes is also possible in mono-mode.

Keywords: review, loco-regional hyperthermia, conservative therapy, palliative therapy, thermochemotherapy, thermoradiation therapy

For citation: Kurpeshev OK, Van Der Zee J. Hyperthermic Methods in Conservative  and Palliative Treatment of Oncological Patients. 

Part 1. Loco-Regional Hyperthermia. Medical Radiology and Radiation Safety. 2022;67(1):87–98.

DOI: 10.12737/1024-6177-2022-67-1-87-98

References

1. Состояние онкологической помощи населению России в 2018 году (под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой). М.: МНИОИ им П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019. 236 стр.  http://www.oncology.ru/service/statistics/[The state of oncological assistance to the population of Russia in 2018 (edited by A. Kaprin, VV. Starinsky and GV. Petrova). Moscow: Herzen Moscow Research Institute – a branch of the Federal State Budget Scientific Research Center for Radiology of the Russian Ministry of Health. 2019. 236 pp. (In Russ.)]. http://www.oncology.ru/service/statistics/]

2. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019. E1-E20. September 27. DOI: https://doi.org/10.1001/jamaoncol.2019.2996.

3. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J. of the National Cancer Institute. 2017;109(9):djx030. DOI: 10.1093/jnci/djx030.

4. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta: American Cancer Society, 2016. Inc. No.865016.

5. Nahum AE. Converting Dose Distributions into Tumour Control Probability Radiation Dose in Radiotherapy from Prescription to Delivery. IAEA, A-1400 Vienna, Austria. 1996: 27-40.

6. Орлова Р.В., Вайзьян Р.И., Иванова А.К., Тихонова Е.К., Зорина Е.Ю. Химиотерапия злокачественных опухолей: проблемы и перспективы // Вопросы онкологии. 2015. № 2(61). С. 244-251. [Orlova RV, Vaizyan RI, Ivanova AK, Tikhonova EK, Zorina EY. Chemotherapy of Malignant Tumors: Problems and Prospects. Problems in Oncology. 2015;61(2):244-51. (In Russ.).] 

7. Поддубная И.В., Орел Н.Ф. Побочные реакции и осложнения противоопухолевой лекарственной терапии. Руководство по химиотерапии опухолевых заболеваний (под ред. Н.И. Переводчиковой и В.А.Горбуновой). М.: Практическая медицина, 2011:425-446. [Poddubnaya IV, Oryol NF. Adverse Reactions and Complications of Antitumor Drug Therapy. Guidelines for the Chemotherapy of Tumor Diseases (ed. NI. Perevodchicova and VA. Gorbunova). Moskow. Practical medicine. 201:425-46. (In Russ.)]

8. Чубенко ВА. Осложнения таргетной терапии // Практическая онкология. 2010. № 3(11). С. 192-202. [Chubenko VA. Complications of Targeted Therapy. Practical Oncology. 2010;11(3):192-202. (In Russ.)]

9. De Angelis CD, Fontanarosa PB. Prescription Drugs, Products Liability, and Preemption of Tort Litigation. JAMA. 2008;300(16):1939-41.

10. Ставровская А.А, Генс Г.П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток // Успехи молекулярной онкологии. 2014. № 1(1). С. 5-11. doi:10.17650/2313-805X.2014.1.1.5-11.[Stavrovskaya AA, Gens GP. Some New Aspects of Studies of Multidrug Resistance of Tumor Cells. Advances in Molecular Oncology. 2014;1(1):5-11. (In Russ.)]. DOI: 10.17650 / 2313-805X.2014.1.1.5-11.

11. Трякин А.А., Федянин М.Ю., Покатаев И.А. 20 лет таргетной терапии солидных опухолей. Успехи и неудачи // Практическая онкология. 2018. № 3(19). С. 183-199. [Tryakin AA, Fedyanin MYu, Pokataev IA. 20 Years of Targeted Therapy of Solid Tumors. Success and Failure. Practical Oncology. 2018;19(3):183-99. (In Russ.)]

12. Zafar SY, Abernethy AP. Financial Toxicity, Part I: A New Name For A Growing Problem. Oncology (Williston Park). 2013;27(2):80-1.

13. Cheng Y, Weng S, Yu L,  Zhu N, Yang M, Yuan Y. The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors. Integrative Cancer Therapies. 2019;18:1-11. DOI 10.1177/1534735419876345.

14. Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей. Часть 4. Экспериментальные основы и практические результаты применения общей гипертермии в лечении химиорезистентных опухолей // Российский онкологический журнал. 2003. № 3. С. 50-53. [Kurpeshev OK, Tsyb AF, Mardynsky YS, Berdov BA. Mechanisms of development and ways of overcoming the chemoresistance of tumors. Part 4. Experimental foundations and practical results of the use of general hyperthermia in the treatment of chemoresistant tumors. Russian Journal of Oncology. 2003;3:50-3.  (In Russ.).]

15. Курпешев О.К, Ван дер Зее Я., Кавагнаро М. Гипертермия опухолей глубокой локализации: возможности ёмкостного метода // Медицинская радиология и радиационная безопасность. 2019;64(4):64–75. DOI: 10.12737/1024-6177-2019-64-4-64-75. DOI: 10.12737 / 1024-6177-2019-64-4-64-75. [Kurpeshev OK, Van der Zee J, Kavagnaro M. Hyperthermia of Tumors of Deep Localization: Possibilities of the Capacitive Method. Medical Radiology and Radiation Safety. 2019;64(4):64-75. (In Russ.). DOI: 10.12737 / 1024-6177-2019-64-4-64-75]

16. Van der Heijden AG, Dewhirst MW. Effects of Hyperthermia in Neutralizing Mechanisms of Drug Resistance in Non-Muscleinvasive Bladder Cancer. Int J Hyperthermia. 2016;32(4):434-45. http://dx.doi.org/10.3109/ 02656736.2016.1155761

17. Курпешев ОК. Закономерности радиосенсибилизирующего и повреждающего эффектов гипертермии на нормальные и опухолевые ткани. Автореф. дисс. докт. мед. наук. Обнинск, 1989. 35 с. [Kurpeshev OK. Patterns of the radiosensitizing and damaging effects of hyperthermia on normal and tumor tissues. Author’s abstract. diss. PhD, MD. Obninsk, 1989. 35 pp. (In Russ.)]

18. Панкратов В.А., Андреев В.Г., Рожнов В.А., Гулидов И.А., Барышев В.В., Буякова М..Е, Вдовина С.Н., Курпешев О.К., Подлесных Н.И. Одновременное применение химио- и лучевой терапии при самостоятельном консервативном и комбинированном лечении больных местно-распространенным раком гортани и гортаноглотки // Сибирский онкологический журнал. 2007. № 1. С. 18-22. [Pankratov VA, Andreev VG, Rozhnov VA. Gulidov IA, Baryshev VV, Buyakova ME. Vdovina SN, Kurpeshev OK, Podlesnykh NI. Simultaneous Use of Chemotherapy and Radiation Therapy in Independent Conservative and Combined Treatment of Patients with Locally Advanced Cancer of the Larynx and Laryngopharynx. Siberian J. Oncology. 2007;1:18-22. (In Russ.).]

19. Van der Zee J, Vujaskovic Z, Kondo M, Sugahara T. Part I. Clinical Hyperthermia. The Kadota Fund International Forum 2004 − Clinical Group Consensus. Int J Hyperthermia. 2008;24(2):111-22.

20. Курпешев О.К., van der Zee J. Локорегионарная гипертермия злокачественных опухолей − методики, термометрия, аппаратура // Медицинская радиология и радиационная безопасность. 2017. 5(62). С. 52-63. DOI: 10.12737/article_59f30321207ef4.88932385. [Кurpeshev ОК, van der Zee J. Locoregional Hyperthermia of Malignant Tumors: Methods, Thermometry, Machines. Medical Radiology and Radiation Safety. 2017;62(5):52-63. (In Russ.). DOI: 10.12737/article_59f303 21207ef4.88932385]

21. Kouloulias V, Triantopoulou S, Vrouvas J, Gennatas K, Ouzounoglou N, Kouvaris J,  Karaiskos P,  Aggelakis P,  Antypas C,  Zygogianni A,  Papavasiliou K,  Platoni K,  Kelekis N. Combined Chemoradiotherapy with Local Microwave Hyperthermia for Treatment of T3N0 Laryngeal Carcinoma: a Retrospective Study with Long-Term Follow-Up. Acta Otorhinolaryngol Ital. 2014;34(3):167-73. PMCID: PMC4035838.

22. Zhu H, Huo X, Chen L. Wang H, Yu H. Clinical Experience with Radio- Chemo- and Hyperthermotherapy Combined Trimodality on Locally Advanced Esophageal Cancer. Molecular and Clinical Oncology. 2013;1:1009-12. DOI: 10.3892/mco.2013.161.

23. Oldenborg S, van Os RM, Van Rij CM,  Crezee J, van de Kamer JB,  Rutgers E, Geijsen ED, Zum vörde sive vörding PJ, Koning CC, Van tienhoven G. Elective Re-Irradiation and Hyperthermia Following Resection of Persistent Locoregional Recurrent Breast Cancer: A Retrospective Study. Int J Hyperthermia 2010;26(2):136-44.

24. Oldenborg S, Griesdoorn V, van Os R,  Kusumanto YH, Oei BS,  Venselaar JL, Geijsen ED, Zum vörde sive vörding PJ, Koning CC, Van tienhoven G. Reirradiation and Hyperthermia for Irresectable Locoregional Recurrent Breast Cancer in Previously Irradiated Area: Size Matters. Radiother Oncol. 2015;117:223-28.

25. Oldenborg S, Rasch CRN, van Os R, Kusumanto YH, Oei BS, Venselaar JL, Heymans MW, ZumVörde Sive Vörding PJ, Crezee H, van Tienhoven G. Reirradiation + Hyperthermia for Recurrent Breast Cancer en Cuirasse. Strahlentherapie und Onkologie. 2018;194:206-14. https://doi.org/10.1007/s00066-017-1241-1247.

26. Linthorst M, van Geel AN, Baaijens M, Ameziane A, Ghidey W, van Rhoon GC, van der Zee J. Re-Irradiation and Hyperthermia After Surgery for Breast Cancer. Radiother. Oncol. 2013;109:188-93.

27. Linthorst M, Baaijens M, Wiggenraad R. Creutzberg C, Ghidey W, van Rhoon GC, van der Zee J. Local Control Rate after the Combination of Reirradiation and Hyperthermia for Irresectable Recurrent Breast Cancer: Results in 248 Patients. Radiother. Oncol. 2015;117:217-22.

28. Notter M, Thomsen AR, Nitsche M, Hermann RM, Wol HA, Habl G, Münch K, Grosu A-L, Vaupel P. Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification. Cancers. 2020;12(3):606-20. DOI: 10.3390/cancers12030606.

29. Linthorst M, van Rhoon GC, van Geel AN, Baaijens M, Ghidey W, Broekmeyer-Reurink MP, van der Zee J. The Tolerance of Reirradiation and Hyperthermia in Breast Cancer patients with reconstructions. Int. J. Hyperthermia. 2012;28(3):267-77. DOI: 10.3109/02656736.2012.663951.

30. Roesch M, Mueller-Huebenthal B. Review: The Role of Hyperthermia in Treating Pancreatic Tumors. Indian J Surg Oncol. 2015 March; 6(1):75–81. DOI: 10.1007/s13193-014-0316-5. 

31. Yanai Y, Yasoshima T, Fukui R, Shishido T, Ezoe E, Furuta Y, Morosawa H, Miya Y, Sato Y, Kondo M. Retrospective Analysis of Hyperthermia Therapy Y. in 47 case of Unresectable Pancreatic Cancer. The 6th Asian Congress of Hyperthermic Oncology & The 31st Japanese Congress of Thermal Medicine at Fukui City, Japan. September 5 (Fri.) − 6 (Sat.). 2014:146. Абстракт GSJ10.

32. Hetzel FW, Mattiello J. Interactions of Hyperthermia with Other Modalities. Medical Physics Monograph. Biological, Physical and Clinical Aspects of Hyperthermia (editors: Paliwal BR, Hetzel FW, Dewhirst MW). Am. Inst. Phys. 1987;16:30–56 (cit. according to [16]).

33. Franckena M, De Wit R, Ansink AC,  Notenboom A, Canters RAM, Fatehi D,  Van Rhoon GC, Van Der Zee J. Weekly Systemic Cisplatin Plus Locoregional Hyperthermia: An Effective Treatment for Patients with Recurrent Cervical Carcinoma in a Previously Irradiated Area. Int J Hyperthermia. 2007;23:443-50. DOI: 10.1080/02656730701549359.

34. Franckena M, Fatehi D, de Bruijne M, Canters RAM, van Norden Y, Mens JW,  Van Rhoon GC, Van Der Zee J. Hyperthermia Dose-Effect Relationship in 420 Patients with Cervical Cancer Treated with Combined Radiotherapy and Hyperthermia. Eur J Cancer. 2009;45(11):1969-78. DOI: 10.1016/j.ejca.2009.03.009.

35. Jones  E, Secord AA, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, Clarke-Pearson D, Soper J, Dewhirst MW., Vujaskovic Z. Intra-Peritoneal Cisplatin and Whole Abdomen Hyperthermia for Relapsed Ovarian Carcinoma. Int J Hyperthermia. 2006;22(2):161–72. DOI: 10.1080/02656730500515270.

36. Milani V, Pazos M, Issels RD, Rahman S, Tschoep K, Schaffer P, Wilkowski R, Duehmke E, Schaffer M.  Radiochemotherapy in Combination with Regional Hyperthermia in Preirradiated Patients with Recurrent Rectal Cancer. Strahlentherapie und Onkologie. 2008;184(3):163-68. DOI: 10.1007/s00066-008-1731-8.

37. Ohguri T, Imada H, Kato F, Yahara K, Morioka T, Nakano K, Korogi Y. Radiotherapy with 8 MHz Radiofrequency-Capacitive Regional Hyperthermia for Pain Relief of Unresectable and Recurrent Colorectal Cancer. Int J Hyperthermia. 2006;22(1):1-14. 

38. Курпешев О.К., Мардынский Ю.С., Максимов С.А. Комбинированное лечение больных раком полости рта с использованием "условно-динамического" режима фракционирования лучевой терапии и локо-регионарной гипертермии // Сибирское медицинское обозрение. 2011. 1(67). С. 80-84. DOI: 10.1080/02656730500381152. [Kurpeshev OK, Mardynsky YS, Maksimov SA. Combined Treatment of Patients with Oral Cancer Using the "Conditionally Dynamic" Mode of Fractionation of Radiation Therapy and Loco-Regional Hyperthermia. Siberian Medical Review. 2011;67(1):80-4. (In Russ.). DOI: 10.1080/02656730500381152]

39. Курпешев О.К., Андреев В.Г., Панкратов В.А., Гулидов И.А., Орлова А.В. Сравнительные результаты консервативной химиолучевой и термохимиолучевой терапии местнораспространенного рака гортани // Вопросы онкологии. 2014 № 5(60). С. 602-606. [Kurpeshev OK, Andreev VG, Pankratov VA, Gulidov IA, Orlova AV. Comparative Results of Conservative Chemoradiation and Thermochemoradiotherapy of Locally Advanced Laryngeal Cancer. Problems in Oncology. 2014;60(5):602-6. (In Russ.).]

40. Li Z, Sun Q, Huang X, Zhang J, Hao J, Li Y, Zhang S. The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer. Open Med. 2018;13:83-9. https://doi.org/10.1515/med-2018-0013.

41. Курпешев О.К., Флоровская Н.Ю., Лебедева Т.В. Результаты паллиативной термохимиотерапии метастазов колоректального рака в печень // Вопросы онкологии. 2016. № 1(62). С. 85-90. [Kurpeshev ОК, Florovskaya NY, Lebedeva ТV. Results of Palliative Thermochemotherapy for Colorectal Cancer Metastases to the Liver. Problems in Oncology. 2016;62(1):85-90. (In Russ.).]

42. Yang W-H, Xie J, Lai Z-Y, Yang M-D, Zhang G-H, Li Y, Mu J-B, Xu J. Radiofrequency Deep Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Chinese Medical J. 2019;132(8):922-7. DOI: 10.1097/CM9.0000000000000156. PMID: 30958433.

43. Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Sato T, Kawamori J, Tanaka Y. Treatment Outcomes of Concurrent Hyperthermia and Chemoradiotherapy for Pancreatic Cancer: Insights into the Significance of Hyperthermia Treatment. Oncology Letters. 2017;13:4959-64.

44. Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R.  Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). The Oncologist. 2019;24:1–10. www.TheOncologist.com.

45. Ott OJ, Schmidt M, Semrau S, Strnad V, Matzel KE, Schneider I, Raptis D, Uter W, Grützmann R, Fietkau R. Chemoradiotherapy with and without Deep Regional Hyperthermia for Squamous Cell Carcinoma of the Anus. Strahlentherapie und Onkologie. 2019;195(7):607-14. DOI: 10.1007/s00066-018-1396-x 

46. Cho C, Wust P, Hildebrandt B, Issels RD, Sehouli J, Kerner T, Deja M, Budach V, Gellermann J. Regional Hyperthermia of the Abdomen in Conjunction with Chemotherapy for Peritoneal Carcinomatosis: Evaluation of Two Annular-Phased-Array Applicators. Int J Hyperthermia. 2008;24(5):399-408. DOI: 10.1080/02656730801929915.

47. Shen H, Li X-D, Wu C-P, Yin Y-M, Wang R-S, Shu Y-Q. The Regimen of Gemcitabine and Cisplatin Combined with Radio Frequency Hyperthermia for Advanced Non-Small Cell Lung Cancer: A Phase II Study. Int J Hyperthermia, February 2011;27(1):27-32. DOI: 10.3109/02656736.2010.500645.

48. Kурпешев O.K., van der Zee J. Анализ результатов рандомизированных исследований по гипертермии в онкологии // Медицинская радиология и радиационная безопасность. 2018. № 3(63). С. 52-67. DOI: 10.12737/article_5b179d60437d54.24079640. [Kurpeshev OK, van der Zee J. Analysis of the Results of Randomized Trials of Hyperthermia in Oncology. Medical Radiology and Radiation Safety. 2018;63(3):52-67. (In Russ.). DOI: 10.12737/article_5b179d60437d54.24079640]

49. Chi MS, Yang KL, Chang YC, Ko H-L, Lin Y-H, Huang S-C, Huang Y-Y, Liao K-W, Kondo M, Chi K-H. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Rad Oncol Biol Phys. 2018;100:78-87. DOI: 10.1016/j.ijrobp.2017.09.030.

50. Li G-X, Lu Z, Sun X-M, Ma C-G., Liu K., Liu J, Guo L, Li P-X. Clinical Effect of Radiofrequency Hyperthermia Combined with Chemotherapy on Stage IV Gastric Cancer. Chinese J. of Cancer Prevention and Treatment. 2010;17:526-28. 

51. Fang H, Zhang Y, Wu Z, Wang X, Wang H, Wang Y, Chai F, Jiang Y, Jin Z, Wan Y, Zhu L, Ma S.  Regional Hyperthermia Combined with Chemotherapy in Advanced Gastric Cancer. Open Med. 2019;14:85-90. https://doi.org/10.1515/med-2019-0012. 

52. Wang Y, Hong W, Che S, Zhang Y, Meng D, Shi F,  Su J,  Yang Y,  Ma H,  Liu R,  Gao Y,  Wang J,  Hui B, Wang J,  Lu J, Wang T,  Liu Z,  Chen H.  Outcomes for Hyperthermia Combined with Concurrent Radiochemotherapy for Patients with Cervical Cancer. Int J Rad Oncol Biol Phys. Published: March 13, 2020. DOI: 10.1016/j.ijrobp.2020.03.006 

53. Datta NR, Pestalozzi B, Clavien P-A, Siebenhüner A, Puric E, Khan S, Mamot C, Riesterer O, Knuchel J, Reiner CS, Bodis S and members of the HEATPAC Trial Group. “HEATPAC J.” – A Phase II Randomized Study of Concurrent Thermochemoradiotherapy Versus Chemoradiotherapy Alone in Locally Advanced Pancreatic Cancer. Radiation Oncology. 2017;12:183. DOI: 10.1186/s13014-017-0923-8.

54. Datta NR, Rogers S, Ordóñez SG, Puric E, Bodis S. Hyperthermia and Radiotherapy in the Management of Head and Neck Cancers: A Systematic Review and Meta-Analysis. Int J Hyperthermia. 2016;32(1):31-40. DOI: 10.3109/02656736.2015.1099746.

55. Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S. Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A SystematicReview and Meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2016; 94:1073-87. DOI: https://doi.org/10.1016/j.ijrobp.2015.12.361.

56. Datta NR, Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S. Hyperthermia and Radiotherapy with or without Chemotherapy in Locally Advanced Cervical Cancer: A Systematic Review with Conventional and Network Meta-Analyses. Int J Hyperthermia. 2016;32(7):809-21. DOI: 10.1080/02656736.2016.1195924. 

57. Baoning Q, Chuandao S, Na S, Xinan W, Yuanping H. Efficacy and Safety of Radio-Chemotherapy Combined with Thermotherapy for Advanced Cervical Cancer in Chinese Women: A Meta-Analysis. Arch. Med. Sci. Civil. Dis. 2017;2:e182–e90. DOI: https://doi.org/10.5114/amscd.2017.72542. 

58. Hu Y, Li Z, Mi D.-H, Cao N, Zu S-W, Wen Z.-Z, Yu X-L, Qu Y. Chemoradiation Combined with Regional Hyperthermia for Advanced Oesophageal Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Pharmacy and Therapeutics. 2017;42:155-64. DOI: 10.1111/jcpt.12498.

59. Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей.  Часть 3. Возможные пути преодоления химиорезистентности опухолей // Российский онкологический журнал. 2003. № 2. С. 50-52. [Kurpeshev OK, Tsyb AF, Mardynsky YS, Berdov B.A. Mechanisms of development and ways of overcoming the chemoresistance of tumors. Part 3. Possible ways to overcome tumor chemoresistance. Russian Journal of Oncology. 2003;2:50-2. (In Russ).] 

60. Курпешев ОК, Van der Zee J. Экспериментальные основы применения гипертермии в онкологии // Медицинская радиология и радиационная безопасность. 2018. № 1(63). С. 57-77. DOI: 10.12737/article_5a8556b4be3e24.36808227. [Kurpeshev OK, Van der Zee J. The Experimental Basis for the Use of Hyperthermia in Oncology. Medical Radiology and Radiation Safety. 2018;63(1):57-77. (In Russ.). DOI: 10.12737/article_5a8556b4be3e24.36808227. (In Russ)]

61. Oei AL, Vriend LEM, Krawczyk PM, Horsman MR, Franken NAP, Crezee J. Targeting Therapy–Resistant Cancer Stem Cells by Hyperthermia. Int J Hyperthermia. 2017;33(4):419-27. DOI: 10.1080/02656736.2017.1279757.

62. Pelicci PG, Dalton P, Orecchia R. Heating Cancer Stem Cells to Reduce Tumor Relapse. Breast Cancer Research. 2011;13:305. DOI: https://doi.org/10.1186/bcr2847.

63. Sakurai H. Tumor Targeting with Hyperthermia. Jpn J Hyperthermic Oncology. 2006;22(2):61-9.

64. Curley SA, Palalon F, Sanders KE, Koshkina NV. The Effects of Non-Invasive Radiofrequency Treatment and Hyperthermia on Malignant and Nonmalignant Cells. Int. J. Environ Res. Public Health. 2014;11(9):9142–53. DOI: 10.3390/ijerph110909142.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The author declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. The article was prepared with equal participatib of authors.

Article received: 18.01.2020. Accepted for publication: 22.05.2021.

 

Medical Radiology and Radiation Safety. 2022. Vol. 67. № 1

Human Mesenchymal Stromal Cells: Characteristics, Radiosensitivity and Effects of Low-Dose Radiation

D.Yu. Usupzhanova, T.A. Astrelina, I.V. Kobzeva, V.A. Brunchukov, A.S. Samoilov

A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: Usupzhanova Daria Yurievna: This email address is being protected from spambots. You need JavaScript enabled to view it.

Annotation

Throughout life a person is inevitably exposed to low doses of ionizing radiation (LDIR) both background radiation and as part of medical treatment and diagnostics, during professional activities, air travel etc. Today the effects of LDIR and the risks of long-term consequences of this impact are increasingly attracting the researchers attention. On the one hand, scientists point to the development of negative consequences, in particular, the accumulation of double-stranded breaks DNA, on the other hand, some studies demonstrating the development of such events as hormesis and adaptive response. Based on this, there is an assumption that in the range of LDIR may exist a non-linear dependence of the effects on the radiation dose, i.e. the effect isn’t proportional to the received dose and that is consistent with the threshold-concept. Today many scientific papers are devoted to this area of research. Special attention is drawn to the effects LDIR on human mesenchymal stromal cells (MSCs) because they are the regenerative reserve of the body. Due to the them ability to self-sustain MSCs can stay in the body for a long time and undergo several rounds of irradiation, accumulating the changes in themselves and passing ones to the next generations of cells since they have the potential to the differentiation. Thus, changes that have occurred in the MSCs affect the human body as a whole. Based on all of the above, it can be concluded that the study of the effects of LDIR on mesenchymal stromal cells of human is actual area of research currently.

Keywords: adaptive response, bystander effect, genomic instability,  mesenchymal stromal cells, radiosensitivity, effects of low radiation doses, radiation hormesis

For citation: Usupzhanova DYu, Astrelina TA, Kobzeva IV, Brunchukov VA, Samoilov AS. Human Mesenchymal Stromal Cells: Characteristics, Radiosensitivity and Effects of Low-Dose Radiation. Medical Radiology and Radiation Safety. 2022;67(1):103-110.

DOI: 10.12737/1024-6177-2022-67-1-103-110

References

1. Squillaro T, Galano G, De Rosa R, Peluso G, Galderisi U. Concise Review: The Effect of Low-Dose Ionizing Radiation on Stem Cell Biology: A Contribution to Radiation Risk. Stem Cells. 2018;36(8):1146-1153. doi:10.1002/stem.2836

2. Fazel R, Krumholz H, Wang Y. Exposure to Low-Dose Ionizing Radiation from Medical Imaging Procedures. J Vasc Surg. 2009;50(6):1526-1527. doi:10.1016/j.jvs.2009.10.095

3. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37(2-4):1-332. doi:10.1016/j.icrp.2007.10.003

4. Thurairajah K, Broadhead M, Balogh Z. Trauma and Stem Cells: Biology and Potential Therapeutic Implications. Int J Mol Sci. 2017;18(3):577. doi:10.3390/ijms18030577

5. Ullah I, Subbarao R, Rho G. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2). doi:10.1042/bsr20150025

6. Aggarwal R, Lu J, J. Pompili V, Das H. Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application. Curr Mol Med. 2012;12(1):34-49. doi:10.2174/156652412798376125

7. Wang Q, Sun B, Wang D et al. Murine Bone Marrow Mesenchymal Stem Cells Cause Mature Dendritic Cells to Promote T-Cell Tolerance. Scand J Immunol. 2008;68(6):607-615. doi:10.1111/j.1365-3083.2008.02180.x

8. Spaggiari G, Capobianco A, Abdelrazik H, Becchetti F, Mingari M, Moretta L. Mesenchymal stem cells inhibit natural killer–cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327-1333. doi:10.1182/blood-2007-02-074997

9. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens. 2007;69(1):1-9. doi:10.1111/j.1399-0039.2006.00739.x

10. Chen L, Tredget E, Wu P, Wu Y. Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing. PLoS One. 2008;3(4):e1886. doi:10.1371/journal.pone.0001886

11. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905

12. Gronthos S, Franklin D, Leddy H, Robey P, Storms R, Gimble J. Surface protein characterization of human adipose tissue-derived stromal cells. J Cell Physiol. 2001;189(1):54-63. doi:10.1002/jcp.1138

13. Friedenstein A, Chailakhjan R, Lalykina K. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Prolif. 1970;3(4):393-403. doi:10.1111/j.1365-2184.1970.tb00347.x

14. Bonab M, Alimoghaddam K, Talebian F, Ghaffari S, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006;7(1):14. doi:10.1186/1471-2121-7-14

15. Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lonning PE et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009; 69(1):5331–5339 doi: 10.1158/0008-5472.CAN-08-4630.

16. Chen G, Yue A, Ruan Z, Yin Y, Wang R, Ren Y, Zhu L. Monitoring the biology stability of human umbilical cord-derived mesenchymal stem cells during long-term culture in serum-free medium. Cell Tissue Bank. 2014; 15(1):513–521  doi: 10.1007/s10561-014-9420-6.

17. Lomax ME, Folkes LK, O'Neill P. Biological consequences of radiation- induced DNA damage: relevance to radiotherapy. Clin. Oncol. (R. Coll. Radiol.). 2013;25(1):578–585. doi: 10.1016/j.clon.2013.06.007. 

18. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of non- homologous end joining and homologous recombination in human cells. DNA Repair (Amst.). 2008;7(1):1765–1771. doi: 10.1016/j.dnarep.2008.06.018. 

19. Solokov M., Neumman R. Human embryonic stem cell responses to ionizing radiation exposures: current state of knowledge and future challenges. Stem Cells Int. 2012;2012:579104 doi: 10.1155/2012/579104. 

20. Prise KM, Saran A. Concise review: stem cell effects in radiation risk. Stem Cells. 2011;29(1):1315–1321. doi: 10.1002/stem.690. 

21. Delacote F, Lopez BS. Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-strand break repair model. Cell Cycle. 2008;7(1):33–38. doi: 10.4161/cc.7.1.5149. 

22. Islam MS, Stemig ME., Takahashi Y, Hui SK. Radiation response of mesenchymal stem cells derived from bone marrow and human pluripotent stem cells. J. Radiat. Res. 2015;56(1):269–277. doi: 10.1093/jrr/rru098. 

23. Nicolay N et al. Mesenchymal stem cells are resistant to carbon ion radiotherapy. Oncotarget. 2015;6(1):2076–2087. doi: 10.18632/oncotarget.2857. 

24. Oliver L et al. Differentiation-related response to DNA breaks in human mesenchymal stem cells. Stem Cells. 2013;31(1):800–807. doi: 10.1002/stem.1336. 

25. Tsvetkova A et al. γH2AX, 53BP1 and Rad51 protein foci changes in mesenchymal stem cells during prolonged X-ray irradiation. Oncotarget. 2017;8(1):64317–64329. doi: 10.18632/oncotarget.19203.

26. Wu P et al. Early passage mesenchymal stem cells display decreased radiosensitivity and increased DNA repair activity. Stem Cells Transl. Med. 2017;6(1):1504–1514. doi: 10.1002/sctm.15-0394. PMID: 28544661.

27. Aypar U, Morgan W, Baulch J. Radiation-induced genomic instability: are epigenetic mechanisms the missing link? Int. J. Radiat. Biol. 2011;87(1):179–191. doi: 10.3109/09553002.2010.522686.

28. Meyer B et al. Histone H3 lysine 9 acetylation obstructs ATM activation and promotes ionizing radiation sensitivity in normal stem cells. Stem Cell Rep. 2016;7(1):1013–1022. doi: 10.1016/j.stemcr.2016.11.004.

29. Armstrong C et al. DNMTs are required for delayed genome instability caused by radiation. Epigenetics. 2012;7(1):892–902. doi: 10.4161/epi.21094.

30. Tang F, Loke W. Molecular mechanisms of low dose ionizing radiation-induced hormesis, adaptive responses, radioresistance, bystander effects, and genomic instability. Int J Radiat Biol. 2015;91(1):13-27. doi: 10.3109/09553002.201 4.937510. 

31. Liu S. On radiation hormesis expressed in the immune system. Critical Reviews in Toxicology. 2003;33(1):431-441. doi: 10.1080/713611045. 

32. Liang X, So YH, Cui J, Ma K, Xu X, Zhao Y, Cai L, Li W. The low-dose ionizing radiation stimulates cell proliferation via activation of the MAPK/ERK pathway in rat cultured mesenchymal stem cells. Journal of Radiation Research. 2011;52(1):380-386. doi: 10.1269/jrr.10121.

33. Truong K, Bradley S, Baginski B, Wilson J, Medlin D, Zheng L, Wilson R, Rusin M, Takacs E, Dean D. The effect of well-characterized, very low-dose x-ray radiation on fibroblasts. PLoS One. 2018;13(1):e0190330. doi: 10.1371/journal.pone.0190330

34. Bernal A, Dolinoy D, Huang D, Skaar D, Weinhouse C, Jirtle R. Adaptive radiation-induced epigenetic alterations mitigated by antioxidants. Journal of the Federation of American Societies for Experimental Biology. 2013;27(1):665-671. doi: 10.1096/fj.12-220350. 

35. Grdina D, Murley J, Miller R, Mauceri H, Sutton H, Thirman M, Li J, Woloschak G, Weichselbaum R. A Manganese Superoxide Dismutase (SOD2)-Mediated Adaptive Response. Radiation Research. 2013;179(1):115-124. doi: 10.1667/RR3126.2. 

36. Takahashi A, Ohnishi K, Asakawa I, Kondo N, Nakagawa H, Yonezawa M, Tachibana A, Matsumoto H, Ohnishi T. Radiation response of apoptosis in C57BL/6N mouse spleen after whole-body irradiation. International Journal of Radiation Biology. 2001;77(1): 939-945. doi: 10.1080/09553000110062873. 

37. Morgan W, Day J, Kaplan M, McGhee E, Limoli C. Genomic instability induced by ionizing radiation. Radiation Research.1996;146(1):247-258. 

38. Pampfer S, Streffer C. Increased chromosome aberration levels in cells from mouse fetuses after zygote X-irradiation. Radiation Biology.1989;55(1):85–92. doi: 10.1080/09553008914550091.

39. Smith L, Nagar S, Kim G, Morgan W. Radiation-induced genomic instability: radiation quality and dose response. Health Physics. 2003;85(1):23-29. doi: 10.1097/00004032-200307000-00006. 

40. McIlrath J, Lorimore S, Coates P, Wright E. Radiation induced genomic instability in immortalized haemopoietic stem cells. International Journal of Radiation Biology.2003;79(1):27–34. 

41. El-Osta, A. The rise and fall of genomic methylation in cancer. Leukemia. 2004;18(1):233–237 doi: 10.1038/sj.leu.2403218. 

42. Matsumoto H, Hamada N, Takahashi A, Kobayashi Y, Ohnishi T. Vanguards of paradigm shift in radiation biology: radiation-induced adaptive and bystander responses. Journal of Radiation Research. 2007;48(1):97–106. doi: 10.1269/jrr.06090. 

43. Klokov D, Criswell T, Leskov K, Araki S, Mayo L, Boothman D. IR- inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutation Research. 2004;568(1):97-110. doi: 10.1016/j.mrfmmm.2004.06.049. 

44. Moore S, Marsden S, Macdonald D, Mitchell S, Folkard M, Michael B, Goodhead D, Prise K, Kadhim M. Genomic instability in human lymphocytes irradiated with individual charged particles: involvement of tumor necrosis factor alpha in irradiated cells but not bystander cells. Radiation Research. 2005;163(1):183-190. doi: 10.1667/rr3298.

45. Marchese M, Hall E. Encapsulated iodine-125 in radiation oncology. II. Study of the dose rate effect on potentially lethal damage repair (PLDR) using mammalian cell cultures in plateau phase. American Journal of Clinical Oncology.1984;7(1):613-616. 

46. Boreham D, Mitchel R. DNA lesions that signal the induction of radioresistance and DNA repair in yeast. Radiation Research. 1991;128(1):19-28. 

47. Piccinini A, Midwood K. DAMPening inflammation by modulating TLR signalling. Mediator inflamm. 2010;2010: 672395 doi: 10.1155/2010/672395.

48. Ilnytskyy Y, Koturbash I, Kovalchuk O. Radiation-induced bystander effects in vivo are epigenetically regulated in a tissue-specific manner. Environ. Mol. Mutagen. 2009;50(2):105-113. doi: 10.1002/em.20440. 

49. Yahyapour R, Amini P, Rezapoor S, Rezaeyan A, Farhood B, Cheki M, Fallah H, Najafi M. Targeting of Inflammation for Radiation Protection and Mitigation. Curr. Mol. Pharmacol. 2018;11(3):203-210. doi: 10.2174/1874467210666171108165641.

50. Zhang J, Liu J, Ren J, Sun T, Mitochondrial DNA induces inflammation and increases TLR9/NF-B expression in lung tissue. Int J Mol Med. 2014;33(4):817-824. doi: 10.3892/ijmm.2014.1650.

51. Yahyapour R, Motevaseli E, Rezaeyan A, Abdollahi H, Farhood B, Cheki M, Najafi M, Villa V. Mechanisms of Radiation Bystander and Non-Targeted Effects: Implications to Radiation Carcinogenesis and Radiotherapy. Curr Radiopharm. 2018;11(1):34-45. doi: 10.2174/1874471011666171229123130. 

52. Kumar Jella K, Rani S, O'Driscoll L, McClean B, Byrne H, Lyng F. Exosomes are involved in mediating radiation induced by- stander signaling in human keratinocyte cells. Radiat. Res. 2014;181(2):138-145. doi: 10.1667/RR13337.1.

53. Xu S, Wang, J, Ding N, Hu W, Zhang X, Wang B, Hua J, Wei W, Zhu Q. Exosome-mediated microRNA transfer plays a role in radiation-induced bystander effect. RNA. Biol. 2015;12(12):1355-1363. doi: 10.1080/15476286.2015.1100795.

54. Ma Y, Zhang L, Rong S, Qu H, Zhang Y, Chang D, Pan H, Wang W. Relation between gastric cancer and protein oxidation, DNA damage, and lipid peroxidation. Oxid. Med. Cell Lon-gev. 2013;2013:543760. doi: 10.1155/2013/543760.

55. Chaudhry M. Real-time PCR analysis of micro-RNA expression in ionizing radiation-treated cells. Cancer Biother. Radiopharm. 2009;24(1):49-56. doi: 10.1089/cbr.2008.0513.

56. Findik D, Song Q, Hidaka H, Lavin M. Protein kinase A inhibitors enhance radiation induced apoptosis. J. Cellular Bio-chem. 1995;57(1):12-21. doi: 10.1002/jcb.240570103.

57. Dong C, He M, Ren R, Xie Y, Yuan D, Dang B, Li W, Shao C. Role of the MAPK pathway in the observed bystander effect in lymphocytes co-cultured with macrophages irradiated with gamma-rays or carbon ions. Life Sci. 2015;127(1):19-25. doi: 10.1016/j.lfs.2015.02.017. 

58. Moon K, Stukenborg G, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107(5):991-998. doi: 10.1002/cncr.22083. 

59. Marozik P, Mothersill C, Seymour C.B, Mosse I, Melnov S. Bystander effects induced by serum from survivors of the Chernobyl accident. Exp. Hematol., 2007;35(4):55-63. doi: 10.1016/j.exphem.2007.01.029.

60. Halimi M, Parsian H, Asghari S, Sariri R, Moslemi D, Yeganeh F, Zabihi E. Clinical translation of human microRNA-21 as a potential biomarker for exposure to ionizing radiation. Transl. Res. 2014;163(6):578-584. doi: 10.1016/j.trsl.2014.01.009.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution: Article was prepared with equal participation of the authors

Article received: 04.05.2021. 

Accepted for publication: 15.10.2021